Nicox's ZERVIATE Approved in China

Nicox has announced that its partner, Ocumension Therapeutics, has received approval from Chinese authorities to commercialize ZERVIATE® (cetirizine ophthalmic solution), 0.24% in China. This eye drop treatment targets ocular itching associated with allergic conjunctivitis.

Emmet Purtill, Nicox's Vice President of Business Development, expressed confidence in Ocumension's ability to rapidly launch ZERVIATE and effectively penetrate the Chinese market. The commercial launch is expected to generate additional revenue for Nicox through royalties ranging from 5% to 9% on Ocumension’s net sales, along with commercial milestones. Ocumension anticipates that ZERVIATE could achieve peak sales exceeding $100 million annually within the next seven years.

ZERVIATE is the first and only eye drop formulation utilizing the antihistamine cetirizine, the active ingredient found in ZYRTEC®. Currently, it is already available in the U.S. for treating ocular itching related to allergic conjunctivitis through Nicox’s U.S. partner, Harrow, Inc. Ocumension highlights that ZERVIATE is particularly beneficial for treating allergic conjunctivitis in young children, addressing a significant medical need in China.

Ocumension plans to produce ZERVIATE at their newly built, state-of-the-art manufacturing facility in Suzhou, China. The product will be marketed by Ocumension’s commercial team, supported by a broad network of national and provincial distribution partners. The market for prescription products for allergic conjunctivitis in China is projected to grow to nearly $500 million by 2030. Nicox holds the exclusive license for ZERVIATE's development and commercialization in China and most Southeast Asian markets. Nicox stands to potentially earn up to $17.2 million in sales milestones in addition to the royalties from Ocumension’s sales.

Nicox is an international ophthalmology company dedicated to developing innovative solutions to maintain vision and improve eye health. Their leading clinical program is NCX 470, a new nitric oxide-donating bimatoprost eye drop aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also generates revenue through VYZULTA® for glaucoma and ZERVIATE® for allergic conjunctivitis, licensed to various partners worldwide, including Bausch + Lomb and Harrow, Inc. Nicox is headquartered in Sophia Antipolis, France, and is listed on Euronext Growth Paris under the ticker symbol ALCOX. The company is part of the CAC Healthcare index.